| Original language | English |
|---|---|
| Pages (from-to) | 83-84 |
| Number of pages | 2 |
| Journal | JAMA surgery |
| Volume | 157 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2022 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Selection of Neoadjuvant Treatment Arms in Trials of Patients with Squamous Cell Cancer of the Esophagus. / Trikalinos, Nikolaos A.; Robinson, Clifford G.; Park, Haeseong.
In: JAMA surgery, Vol. 157, No. 1, 01.2022, p. 83-84.Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Selection of Neoadjuvant Treatment Arms in Trials of Patients with Squamous Cell Cancer of the Esophagus
AU - Trikalinos, Nikolaos A.
AU - Robinson, Clifford G.
AU - Park, Haeseong
N1 - Funding Information: Conflict of Interest Disclosures: Dr Trikalinos is an institutional principal investigator for trials supported by Exelixis, Merck, Novartis, Bristol Myers Squibb, and Elevar Therapeutics outside the submitted work. Dr Robinson reported personal fees from Varian Consulting, AstraZeneca, and EMD Serono outside the submitted work; personal fees and stock and other ownership interests from Radialogica outside the submitted work; travel, accommodations, and expenses from Siemens Healthineers; and has patent for noninvasive imaging and treatment system for cardiac arrhythmias WO 2017078757 A1/ US Provisional Application No. 62/598,162 entitled System and Method for Determining Segments for Ablation. Dr Park reported institutional grants from Ambrx, Amgen, Aprea Therapeutics, Array BioPharma, Bayer, BeiGene, BJ Bioscience, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly and Company, Elicio Therapeutics, EMD Serono, Genentech, Gilead Sciences, GlaxoSmithKline, Gossamer Bio, Hoffman-LaRoche, Hutchison MediPharma, ImmuneOncia Therapeutics, Incyte, Jounce Therapeutics, MabSpace Biosciences, MacroGenics, MedImmune, Medivation, Merck, Mirati Therapeutics, Novartis, Oncologie, Pfizer, PsiOxus, Puma, Regeneron Pharmaceuticals, Seagen, Synermore Biologics, Taiho Pharmaceutical, Top Alliance Biosciences, Turning Point Therapeutics, Vedanta Biosciences, Vertex Pharmaceuticals, and Xencor outside the submitted work.
PY - 2022/1
Y1 - 2022/1
UR - http://www.scopus.com/inward/record.url?scp=85115853686&partnerID=8YFLogxK
U2 - 10.1001/jamasurg.2021.4532
DO - 10.1001/jamasurg.2021.4532
M3 - Letter
C2 - 34550349
AN - SCOPUS:85115853686
VL - 157
SP - 83
EP - 84
JO - JAMA Surgery
JF - JAMA Surgery
SN - 2168-6254
IS - 1
ER -